Feb 20 (Reuters) - Immunic Inc IMUX.O:
IMMUNIC'S ORAL IMU-856 DEMONSTRATED DOSE-DEPENDENT INCREASE OF GLP-1 IN CELIAC DISEASE PATIENTS AND CORRESPONDING EFFECTS IN PRECLINICAL TESTING
IMMUNIC INC: DOSE-DEPENDENT REDUCTION OF BODY WEIGHT GAIN AND FOOD CONSUMPTION OBSERVED IN PRECLINICAL STUDY
IMMUNIC: DOSE-DEPENDENT INCREASE OF ENDOGENOUS GLP-1 LEVELS OBSERVED IN POST HOC ANALYSIS OF PATIENTS FROM PHASE 1B CLINICAL TRIAL IN CELIAC DISEASE
Source text: ID:nPn12yQH3a
Further company coverage: IMUX.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。